NASDAQ:ICCM IceCure Medical (ICCM) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free ICCM Stock Alerts $0.78 +0.01 (+0.66%) (As of 11:18 AM ET) Add Compare Share Share Today's Range$0.75▼$0.8150-Day Range$0.74▼$1.3552-Week Range$0.52▼$1.57Volume74,622 shsAverage Volume514,276 shsMarket Capitalization$35.36 millionP/E RatioN/ADividend YieldN/APrice Target$2.95 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get IceCure Medical alerts: Email Address IceCure Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside283.2% Upside$2.95 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 starsMedical Sector466th out of 913 stocksSurgical & Medical Instruments Industry57th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingIceCure Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIceCure Medical has only been the subject of 2 research reports in the past 90 days.Read more about IceCure Medical's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.74% of the float of IceCure Medical has been sold short.Short Interest Ratio / Days to CoverIceCure Medical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IceCure Medical has recently decreased by 35.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIceCure Medical does not currently pay a dividend.Dividend GrowthIceCure Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICCM. Previous Next 3.3 News and Social Media Coverage News SentimentIceCure Medical has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IceCure Medical this week, compared to 2 articles on an average week.Search Interest3 people have searched for ICCM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IceCure Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.44% of the stock of IceCure Medical is held by insiders.Percentage Held by InstitutionsOnly 0.62% of the stock of IceCure Medical is held by institutions.Read more about IceCure Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IceCure Medical are expected to grow in the coming year, from ($0.28) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IceCure Medical is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IceCure Medical is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIceCure Medical has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IceCure Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About IceCure Medical Stock (NASDAQ:ICCM)IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Read More ICCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICCM Stock News HeadlinesJune 18 at 8:30 AM | prnewswire.comIceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024June 12, 2024 | prnewswire.comPositive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.June 11, 2024 | americanbankingnews.comAnalysts Set Expectations for IceCure Medical Ltd's Q1 2025 Earnings (NASDAQ:ICCM)June 4, 2024 | prnewswire.comFDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness PlanMay 28, 2024 | prnewswire.comIceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024May 21, 2024 | prnewswire.comIceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024May 21, 2024 | prnewswire.comIceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024June 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.May 20, 2024 | prnewswire.comIceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company ShowcaseMay 14, 2024 | finance.yahoo.comHere's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This YearMay 7, 2024 | prnewswire.comIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published GloballyApril 19, 2024 | finance.yahoo.comHofseth Biocare ASA: HBC ANNUAL REPORT 2023April 15, 2024 | finance.yahoo.comIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerApril 6, 2024 | markets.businessinsider.comIcecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory MilestonesApril 5, 2024 | seekingalpha.comIceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call TranscriptApril 4, 2024 | uk.investing.comIceCure seeks FDA clearance for new cryoablation systemApril 3, 2024 | prnewswire.comIceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing ClearanceApril 2, 2024 | prnewswire.comIceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with CryoprobesMarch 27, 2024 | prnewswire.comIceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024March 19, 2024 | markets.businessinsider.comIceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive ResultsMarch 19, 2024 | finance.yahoo.comIceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to LumpectomyMarch 12, 2024 | prnewswire.comIceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient OutcomesMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 5, 2024 | markets.businessinsider.comIceCure Medical: Strong Buy on Promising Clinical Results and Positive FDA DevelopmentsMarch 4, 2024 | prnewswire.comIceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024See More Headlines Receive ICCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IceCure Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/28/2024Today6/17/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:ICCM CUSIPN/A CIK1584371 Webwww.icecure-medical.com Phone972-4623-0333Fax972-4623-0222Employees71Year FoundedN/APrice Target and Rating Average Stock Price Target$2.95 High Stock Price Target$3.00 Low Stock Price Target$2.90 Potential Upside/Downside+283.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net Margins-444.30% Pretax Margin-453.76% Return on Equity-101.66% Return on Assets-77.73% Debt Debt-to-Equity Ratio0.03 Current Ratio3.39 Quick Ratio2.88 Sales & Book Value Annual Sales$3.23 million Price / Sales10.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book2.85Miscellaneous Outstanding Shares45,620,000Free Float44,510,000Market Cap$35.12 million OptionableNot Optionable Beta0.66 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Eyal Shamir (Age 63)CEO & Director Comp: $416.36kMr. Ronen Tsimerman CPA (Age 55)CFO & COO Comp: $306.4kMs. Tlalit Bussi Tel-Tzure (Age 53)Vice President of Business Development & Global Marketing Comp: $248.44kMs. Merav Nir Dotan (Age 55)Vice President of Human Resources Comp: $197.96kMs. Galit Malik (Age 51)Vice President of Operations & Service Key CompetitorsQuipt Home MedicalNASDAQ:QIPTTELA BioNASDAQ:TELABrainsWayNASDAQ:BWAYKORU Medical SystemsNASDAQ:KRMDBlueRiver AcquisitionNYSE:BLUAView All Competitors ICCM Stock Analysis - Frequently Asked Questions Should I buy or sell IceCure Medical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCM shares. View ICCM analyst ratings or view top-rated stocks. What is IceCure Medical's stock price target for 2024? 2 brokers have issued 1-year price objectives for IceCure Medical's shares. Their ICCM share price targets range from $2.90 to $3.00. On average, they expect the company's stock price to reach $2.95 in the next year. This suggests a possible upside of 283.2% from the stock's current price. View analysts price targets for ICCM or view top-rated stocks among Wall Street analysts. How have ICCM shares performed in 2024? IceCure Medical's stock was trading at $1.07 on January 1st, 2024. Since then, ICCM shares have decreased by 28.0% and is now trading at $0.7699. View the best growth stocks for 2024 here. Are investors shorting IceCure Medical? IceCure Medical saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 156,400 shares, a decrease of 35.7% from the May 15th total of 243,200 shares. Based on an average daily volume of 413,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.7% of the shares of the company are short sold. View IceCure Medical's Short Interest. When is IceCure Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ICCM earnings forecast. How were IceCure Medical's earnings last quarter? IceCure Medical Ltd (NASDAQ:ICCM) posted its quarterly earnings results on Tuesday, May, 28th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The firm earned $0.74 million during the quarter, compared to the consensus estimate of $0.80 million. IceCure Medical had a negative net margin of 444.30% and a negative trailing twelve-month return on equity of 101.66%. During the same period in the prior year, the business posted ($0.08) EPS. How do I buy shares of IceCure Medical? Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ICCM) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IceCure Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share IceCure Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.